CHILDHOOD CKD PREVENTION PROGRAM IN TAIWAN: WHAT ARE WE GOING TO DO?. You-Lin Tain MD, PhD, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan. Purposes. (1)Intervention : which, when, and why ? (2)CV measurement (3)Efficiency of ACEI/ARB in CKD progression
01 / 90CHILDHOOD CKD PREVENTION PROGRAM IN TAIWAN: WHAT ARE WE GOING TO DO?
1 / 17
Télécharger la présentation
CHILDHOOD CKD PREVENTION PROGRAM IN TAIWAN: WHAT ARE WE GOING TO DO?
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation
Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement.Téléchargez la présentation en cliquant sur ce lien.Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.
Purposes • (1)Intervention:which, when, and why? • (2)CV measurement • (3)Efficiency of ACEI/ARB in CKD progression • (4)Cerebral accident in ESRD children: marker • (5) Primary prevention: • 1. Identify high risk group • 2. how to maintain GFR • (6) Early detection: how and why? • (7) Steering committee?
Screening for kidney disease in children on World Kidney Day in Jalisco, Mexico Koshy et al., PN, 2009 • 240 children: 8.9 ± 4.1 years; 44.2% male • Proteinuria: 16.1% • Hematuria:17.5% • BMI > 95th percentile for age: 15% • Systolic hypertension: ~7% • Reduced GFR (<60ml/min; CKD stage 3): 1.7% • CKD1-3 • ~15-20%
Criteria How to screen? What kinds of screen? Which population? Intervention OR prevention Subcommittee Iseki K, Int Med, 2008
Outlines • Cr-based eGFR • Questionnaire design • Which phenotype: High risk group • CKD screen: which parameter(s) • Global status of CKD prevention programs in children • Intervention: ACEi, ARB, OR? • CVD in CKD • Sub-committee OR interesting topic • 林: FGF-23, Ghrelin • 邱: Solitary kidney outcome/LN/Cystic kidney • 田: ADMA and SDMA
Outlines • Cr-based eGFR • Questionnaire design • Which phenotype: High risk group • CKD screen: which parameter(s) • Global status of CKD prevention programs in children • Intervention: ACEi, ARB, OR? • CVD in CKD • Sub-committee OR interesting topic • 林: FGF-23, Ghrelin • 邱: Solitary kidney outcome/LN/Cystic kidney • 田: ADMA and SDMA
Schwartz Formula Schwartz et al, Pediatrics 58:259,1976 • GFR (mL/min/1.73 m2) = k (Height) / Serum Creatinine • k = Constant • k = 0.33 in premature infants • k = 0.45 for infant • k = 0.70 for pubertal males • k = 0.55 for all other children • Height in cm • Serum Creatinine in mg/dL
Creatinine Standardization Recommendations by NKDEP Clinical Chemistry 2006;52(1):5-18. • Jaffe Cr assay • Enzymatic Cr assay • HPLC • IDMS: Cr assays that are traceable to an isotope dilution mass spectroscopy (IDMS) reference measurement procedure. • IDMS-traceable Cr << Jaffe Cr • overestimate GFR by 20% to 40%
Calculating eGFR for children http://www.nkdep.nih.gov/labprofessionals/labgfr_children.htm • The older equations for eGFR in children and infants will no longer be valid. • Blood creatinine values will generally be lower for methods that have been calibrated to be traceable to an IDMS reference-measurement procedure. • Not to estimate GFR for children when using an alkaline picrate (“Jaffe”) method with calibration traceable to IDMS. • The interim Schwartz equation (k=0.41) is intended only for enzymatic creatinine methods with calibration traceable to IDMS.
Outlines • Cr-based eGFR • Questionnaire design • Which phenotype: High risk group • CKD screen: which parameter(s) • Global status of CKD prevention programs in children • Intervention: ACEi, ARB, OR? • CVD in CKD • Sub-committee OR interesting topic • 林: FGF-23, Ghrelin • 邱: Solitary kidney outcome/LN/Cystic kidney • 田: ADMA and SDMA
High Risk Groups • Hypodysplastic renal disease, VUR • ItalKid • Hematuria, albuminuria, obesity, hypertension • Haysom et al., AJKD, 2009 (Australia) • Low birth weight, nephron number, and kidney disease. • Brenner et al., AJKD, 1994 • ~7% LBW per year in Taiwan • DM type 1 &2 • ~10/100,000 children in Taiwan
Status of CKD Prevention Programs Smith et al., KI, 2008 • International Federation of Kidney Foundations (IFKF) survey: 28 countries response (56%) • Most countries are not focused on children • KEEP - Kidney Early Evaluation Program - USA • KEY - Kidney Evaluation for You - Australia • IKEAJ - International Kdiney Early Evaluation Program – Japan • NICE guideline – UK • …….. • Mass Urinary Screening: Taiwan, Japan, Korea…. • Chronic Kidney Disease in Children (CKiD) study- USA • Italkid Project- Italy
Chronic Kidney Disease in Children (CKiD) study • Glomerular filtration rate measurement and estimation in chronic kidney disease. • Pediatr Nephrol. 2007 Nov;22(11):1839-48. • Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. • Clin J Am Soc Nephrol. 2006 Sep;1(5):1006- • Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. • Pediatr Nephrol. 2009 Jan;24(1):113-9. • New Equations to Estimate GFR in Children with CKD. • J Am Soc Nephrol. 2009 Mar;20(3):629-37.
Specific Aims • Identify risk factors for the progression of CKD • Characterize the impact of CKD on neurodevelopment, cognitive abilities, and behavior • Identify the prevalence and the evolution of CV disease risk factors in children with CKD • Examine the effects of declining GFR on growth
Italkid: Started in 1990 • Urea percentiles in children with chronic renal failure. Data from the ItalKid project. • Pediatr Nephrol. 2003 Mar;18(3):261-5. • Epidemiology of chronic renal failure in children: data from the ItalKid project. • Pediatrics. 2003 Apr;111(4 Pt 1):e382-7. • The probability of ESRD by age 20 years was 68% (eGFR<75=CKD stage 2B-5) • Severe vesicoureteral reflux and chronic renal failure: a condition peculiar to male gender? • J Pediatr. 2004 May;144(5):677-81.
Italkid • Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. • Pediatr Nephrol. 2004 Feb;19(2):172-7. • Long-term outcome of VUR associated chronic renal failure in children. Data from the ItalKid Project. • The probability of ESRD by age 20 years was 56% (eGFR<75=CKD stage 2B-5) • J Urol. 2004 Jul;172(1):305-10.
Italkid • Prescription of drugs blocking the renin-angiotensin system in Italian children. • Pediatr Nephrol. 2007 Jan;22(1):144-8. • No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid. • Nephrol Dial Transplant. 2007 Sep;22(9):2525-30.
Prevention of CKD in Children Vijayakumar et al., Indian J Nephrol, 2007 • Primary • Reduce exposure to factors that cause renal disease • Reduce antenatal exposure to infections, drugs • Prevention of inheritable renal disease by genetic counseling • Prevention of obesity, dyslipidemia • Early detection/management of hypertension and DM • Secondary • Appropriate measures at various stages of CKD • Tertiary • Reduction of complications impairments or disabilities • Requiring RRT
Outlines • Cr-based eGFR • Questionnaire design • Which phenotype: High risk group • CKD screen: which parameter(s) • Global status of CKD prevention programs in children • Intervention: ACEi, ARB, OR? • CVD in CKD • Sub-committee OR interesting topic • 林: FGF-23, Ghrelin • 邱: Solitary kidney outcome/LN/Cystic kidney • 田: ADMA and SDMA
End-point: Hypertension • The use of ACEI/ARB in children with diabetes and microalbuminuria or proteinuric renal disease. • The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents , Pediatrics, 2004
ACEI/ARB for Hypertension in Children The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents , Pediatrics, 2004